A man and a woman walk into an obesity clinic with identical BMIs of 37. They get the same dietary counseling, the same caloric targets, the same follow-up schedule. One of them is being undertreated for the specific way their body is killing them. According to research presented at the European Congress on Obesity in Istanbul this May, we may not even know which one.
The study, led by Dr. Zeynep Pekel at Dokuz Eylul University, tracked 1,134 adults with obesity: 886 women averaging 45 years old and 248 men averaging 41. The methodology is straightforward observational work, not a randomized controlled trial, and the sample skews heavily female, which limits what you can conclude. Those caveats matter. But the signal is clear enough to take seriously.
The Fat You Cannot See Is the Fat That Kills You
Men in the study carried significantly more visceral fat, the kind that wraps around the liver, pancreas, and intestines and drives metabolic disease. Their average waist circumference was 120 cm versus 108 cm for women. Their liver enzymes, ALT and GGT, were substantially elevated. Triglycerides and creatinine followed the same pattern. These are not abstract numbers; elevated liver enzymes in an obese man are a warning sign for non-alcoholic fatty liver disease, which can progress to cirrhosis without a single obvious symptom.
Women in the study showed a different risk profile entirely. Total cholesterol averaged 215 mg/dL versus 203 mg/dL in men. LDL ran 130 versus 123. Inflammatory markers, specifically C-reactive protein and erythrocyte sedimentation rate, were higher in women. Oestrogen shapes where fat gets stored, pushing it subcutaneously rather than viscerally, but that hormonal protection comes with a trade-off: a more active immune response that, when chronically elevated, damages cardiovascular tissue over years.
Dr. Pekel's framing is careful and correct: "sex differences are a powerful player in the pathology and course of obesity." The finding is not that obesity is worse for one sex. The risk patterns differ in type and distribution, which means the clinical targets differ too.
BMI Is Doing Too Much Work Here
The men in this study had a slightly higher average BMI (37.5 versus 36 kg/m²) despite carrying a qualitatively different disease burden. That gap should embarrass anyone still using BMI as a primary clinical metric. A number that cannot distinguish between visceral fat accumulation and subcutaneous fat accumulation is not measuring what we need it to measure.
To be fair to the current standard of care: the evidence base for sex-specific obesity interventions is genuinely thin. Dr. Pekel's team acknowledged that "these findings need to be confirmed in other patient groups." A single Turkish cohort, even a well-designed one, is not the basis for rewriting clinical guidelines. That is the honest position.
But here is what I will not concede: the absence of confirmed sex-specific protocols is not a reason to keep treating a 45-year-old woman with high LDL and elevated inflammatory markers the same way you treat a 41-year-old man with a fatty liver and a 120 cm waist. The biological mechanisms, oestrogen's role in fat distribution, the X chromosome's contribution to immune activity, are not speculative. They are established physiology that obesity medicine has been slow to operationalize.
Globally, roughly 1 in 3 women and 1 in 4 men live with metabolic syndrome. Those are not the same condition wearing the same face. Obesity researchers need to fund sex-stratified trials. Clinicians need to stop waiting for perfect evidence before asking which risk pattern their patient actually has. The study from Istanbul is early. The question it raises is not.
